E-LIB Suche - Ergebnisse für: Riedell, P. A.

1

NATHALI‐01: A PHASE 1/2A TRIAL OF UCART20X22, AN ALLOGENEIC..:

Bachy, E. ; Ramakrishnan, A. ; Thieblemont, C....
Hematological Oncology. 41 (2023) S2 - p. 825-826 , 2023

Link: https://doi.org/10.1002/..

2

KI‐67 PROLIFERATION PATTERNS ARE PREDICTIVE OF EARLY PROGRE..:

Rojek, A. E. ; Venkataraman, G. ; Fabi, L....
Hematological Oncology. 41 (2023) S2 - p. 682-683 , 2023

Link: https://doi.org/10.1002/..

3

Health‐related quality of life in patients with relapsed or..:

Maloney, D. G. ; Siddiqi, T. ; Fakhri, B....
Hematological Oncology. 41 (2023) S2 - p. 538-541 , 2023

Link: https://doi.org/10.1002/..

4

LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCY..:

Siddiqi, T. ; Maloney, D. G. ; Kenderian, S. S....
Hematological Oncology. 41 (2023) S2 - p. 60-62 , 2023

Link: https://doi.org/10.1002/..

5

PCR78 Establishing Meaningful Change Thresholds for EORTC Q..:

Eliason, L. ; Fofana, F. ; Wang, L...
Value in Health. 26 (2023) 12 - p. S464 , 2023

Link: https://doi.org/10.1016/..

6

Timing of Radiation Therapy and Clinical Outcomes in Lympho..:

Rajeev-Kumar, G. ; Gao, G. ; McKeever, M.R...
International Journal of Radiation Oncology*Biology*Physics. 114 (2022) 3 - p. e348 , 2022

Link: https://doi.org/10.1016/..

7

PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RE..:

Nowakowski, G. S. ; Yoon, D. H. ; Joffe, E....
HemaSphere. 6 (2022) - p. 1982-1983 , 2022

Link: https://doi.org/10.1097/..

8

S258: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TH..:

Sehgal, A. ; Hoda, D. ; Riedell, P. A....
HemaSphere. 6 (2022) - p. 159-160 , 2022

Link: https://doi.org/10.1097/..

9

S212: PHASE I STUDY OF YTB323, A CHIMERIC ANTIGEN RECEPTOR ..:

Dickinson, M. ; Kwon, M. ; Briones, J....
HemaSphere. 6 (2022) - p. 113-114 , 2022

Link: https://doi.org/10.1097/..

10

PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLEC..:

Fowler, N. H. ; Dickinson, M. ; Martinez‐Lopez, J....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

11

EFFICACY AND SAFETY OF TISAGENLECLEUCEL (TISA‐CEL) IN ADULT..:

Schuster, S. J. ; Dickinson, M. ; Dreyling, M....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

12

SAFETY AND EFFICACY OF TISAGENLECLEUCEL PLUS PEMBROLIZUMAB ..:

Jaeger, U. ; Worel, N. ; McGuirk, J. P....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

13

Results of Phase I/II VMAT-TMI Dose Escalation Study Of Pat..:

Partouche, J. ; Hasan, Y. ; Sullivan, M....
International Journal of Radiation Oncology*Biology*Physics. 108 (2020) 3 - p. e757 , 2020

Link: https://doi.org/10.1016/..

14

ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFET..:

Dickinson, M. ; Popplewell, L. ; Kolstad, A....
Hematological Oncology. 37 (2019) S2 - p. 559-560 , 2019

Link: https://doi.org/10.1002/..

15

PORTIA: A PHASE 1B STUDY EVALUATING SAFETY AND EFFICACY OF ..:

Jaeger, U. ; McGuirk, J. ; Worel, N....
Hematological Oncology. 37 (2019) S2 - p. 560-560 , 2019

Link: https://doi.org/10.1002/..